Real-world Experience of Embolization for Intracranial Tumors in Japan: Analysis of 2,756 Cases from Japanese Registry of NeuroEndovascular Therapy 4.

IF 2.3 4区 医学 Q2 CLINICAL NEUROLOGY
Neurologia medico-chirurgica Pub Date : 2025-09-15 Epub Date: 2025-07-31 DOI:10.2176/jns-nmc.2025-0081
Jun Haruma, Kenji Sugiu, Tomohito Hishikawa, Yuta Soutome, Yuki Ebisudani, Ryu Kimura, Hisanori Edaki, Masato Kawakami, Satoshi Murai, Masafumi Hiramatsu, Shota Tanaka, Tetsu Satow, Koji Iihara, Hirotoshi Imamura, Akira Ishii, Yuji Matsumaru, Chiaki Sakai, Shinichi Yoshimura, Nobuyuki Sakai
{"title":"Real-world Experience of Embolization for Intracranial Tumors in Japan: Analysis of 2,756 Cases from Japanese Registry of NeuroEndovascular Therapy 4.","authors":"Jun Haruma, Kenji Sugiu, Tomohito Hishikawa, Yuta Soutome, Yuki Ebisudani, Ryu Kimura, Hisanori Edaki, Masato Kawakami, Satoshi Murai, Masafumi Hiramatsu, Shota Tanaka, Tetsu Satow, Koji Iihara, Hirotoshi Imamura, Akira Ishii, Yuji Matsumaru, Chiaki Sakai, Shinichi Yoshimura, Nobuyuki Sakai","doi":"10.2176/jns-nmc.2025-0081","DOIUrl":null,"url":null,"abstract":"<p><p>Embolization of intracranial tumors is predominantly performed in Japan, primarily before neurosurgical resection. The Japanese Registry of NeuroEndovascular Therapy (JR-NET) Study Group, established in 2005, aims to clarify the factors influencing the outcomes of neuroendovascular treatment. Japanese Registry of NeuroEndovascular Therapy 4 is a nationwide, multicenter retrospective observational study that evaluates real-world data on intracranial tumor embolization in Japan. Japanese Registry of NeuroEndovascular Therapy 4 is based on data collected from 166 neurosurgical centers in Japan between January 2015 and December 2019. Of 63,230 patients, 2,664 (4.2%) with intracranial tumors underwent embolization. The primary endpoint was the proportion of patients with a modified Rankin scale (mRS) score of 0-2 at 30 days post-procedure. Secondary endpoints included procedure-related complications. Among the 2,664 patients, 61 records lacked sufficient data, leaving 2,603 patients (1,612 females, median age: 61 years [interquartile range 51-71]). The proportion of patients with mRS scores ≤2 at 30 days after the procedure was 86.9%. The overall incidence of procedure-related complications was 4.8%, with 1.8% hemorrhagic, 2.0% ischemic, and 1.0% classified as other complications. In the multivariate analysis, general anesthesia and embolization of vessels other than the external carotid artery were identified as risk factors for the development of complications. Meningioma cases had a complication rate of 4.3%, with major complications occurring in 3.5%. Hemangioblastoma cases had a 14.9% complication rate, with major complications at 9.9%. Japanese Registry of NeuroEndovascular Therapy 4 provides comprehensive real-world data on intracranial tumor embolization in Japan, identifying risk factors to inform and improve the safe practice of intracranial tumor embolization in neuroendovascular therapy.</p>","PeriodicalId":19225,"journal":{"name":"Neurologia medico-chirurgica","volume":" ","pages":"396-406"},"PeriodicalIF":2.3000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497513/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologia medico-chirurgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2176/jns-nmc.2025-0081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Embolization of intracranial tumors is predominantly performed in Japan, primarily before neurosurgical resection. The Japanese Registry of NeuroEndovascular Therapy (JR-NET) Study Group, established in 2005, aims to clarify the factors influencing the outcomes of neuroendovascular treatment. Japanese Registry of NeuroEndovascular Therapy 4 is a nationwide, multicenter retrospective observational study that evaluates real-world data on intracranial tumor embolization in Japan. Japanese Registry of NeuroEndovascular Therapy 4 is based on data collected from 166 neurosurgical centers in Japan between January 2015 and December 2019. Of 63,230 patients, 2,664 (4.2%) with intracranial tumors underwent embolization. The primary endpoint was the proportion of patients with a modified Rankin scale (mRS) score of 0-2 at 30 days post-procedure. Secondary endpoints included procedure-related complications. Among the 2,664 patients, 61 records lacked sufficient data, leaving 2,603 patients (1,612 females, median age: 61 years [interquartile range 51-71]). The proportion of patients with mRS scores ≤2 at 30 days after the procedure was 86.9%. The overall incidence of procedure-related complications was 4.8%, with 1.8% hemorrhagic, 2.0% ischemic, and 1.0% classified as other complications. In the multivariate analysis, general anesthesia and embolization of vessels other than the external carotid artery were identified as risk factors for the development of complications. Meningioma cases had a complication rate of 4.3%, with major complications occurring in 3.5%. Hemangioblastoma cases had a 14.9% complication rate, with major complications at 9.9%. Japanese Registry of NeuroEndovascular Therapy 4 provides comprehensive real-world data on intracranial tumor embolization in Japan, identifying risk factors to inform and improve the safe practice of intracranial tumor embolization in neuroendovascular therapy.

日本颅内肿瘤栓塞治疗的实际经验:来自日本神经血管内治疗登记的2756例病例分析
栓塞颅内肿瘤在日本主要是在神经外科手术切除前进行。日本神经血管内治疗注册(JR-NET)研究组成立于2005年,旨在阐明影响神经血管内治疗结果的因素。Japan Registry of NeuroEndovascular Therapy 4是一项全国性、多中心的回顾性观察性研究,旨在评估日本颅内肿瘤栓塞的真实数据。日本神经血管内治疗登记处基于2015年1月至2019年12月期间从日本166个神经外科中心收集的数据。在63230例患者中,2664例(4.2%)颅内肿瘤患者接受了栓塞治疗。主要终点是术后30天改良Rankin量表(mRS)评分为0-2分的患者比例。次要终点包括手术相关并发症。在2664例患者中,61例记录缺乏足够的数据,剩余2603例患者(女性1612例,中位年龄61岁[四分位数间距51-71])。术后30天mRS评分≤2分的患者占86.9%。手术相关并发症的总发生率为4.8%,其中出血性1.8%,缺血性2.0%,其他并发症1.0%。在多因素分析中,全身麻醉和栓塞颈外动脉以外的血管是并发症发生的危险因素。脑膜瘤并发症发生率为4.3%,主要并发症发生率为3.5%。血管母细胞瘤患者并发症发生率为14.9%,主要并发症发生率为9.9%。Japan Registry of NeuroEndovascular Therapy 4提供了日本颅内肿瘤栓塞的全面真实数据,识别危险因素,为颅内肿瘤栓塞在神经血管内治疗中的安全实践提供信息和改进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurologia medico-chirurgica
Neurologia medico-chirurgica 医学-临床神经学
CiteScore
3.70
自引率
10.50%
发文量
63
审稿时长
3-8 weeks
期刊介绍: Information not localized
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信